poisar

Stocks · News reference

ImmunityBio and Rafa Laboratories Receive Israeli Ministry of Health Approval for ANKTIVA Plus BCG

Fiscal.ai

ImmunityBio and Rafa Laboratories announced that the Israeli Ministry of Health has approved ANKTIVA in combination with BCG for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaVandana Singh

    ImmunityBio Reports Wider Quarterly Loss

    ImmunityBio stock falls as Q3 revenue misses estimates, despite positive ANKTIVA bladder cancer trial results and Israeli approval.